Mobile

A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-42160443 in Subjects With Postherpetic Neuralgia and Post-Trau...

Mise à jour : Il y a 4 ans
Référence : EUCTR2008-007478-39

A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-42160443 in Subjects With Postherpetic Neuralgia and Post-Traumatic Neuralgia, Followed by a Double Blind Safety Extension and an Open-Label Safety Extension

Femme et Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

• To evaluate the analgesic efficacy of JNJ-42160443 (1, 3, and 10 mg; administered as a single, subcutaneous injection every 28 days) in reducing average pain intensity, in subjects with postherpetic neuralgia • To evaluate the safety and tolerability of multiple doses of JNJ-42160443 (1, 3, and 10 mg), when administered as a single, subcutaneous injection every 28 days to subjects with postherpetic neuralgia for up to 2 years

Critère d'inclusion

  • Postherpetic Neuralgia and Post-Traumatic Neuralgia

Liens